Anúncio
Anúncio

VVOS

VVOS logo

Vivos Therapeutics, Inc. Common Stock

2.19
USD
Patrocinado
-0.08
-3.52%
08 de jan., 15:56 UTC -5
Encerrado
exchange

Pós-Mercado

2.18

-0.01
-0.68%

Relatórios de Lucros VVOS

Rácio de surpresa positiva

VVOS separação 8 de 19 últimas estimativas.

42%

Próximo Relatório

Data do Próximo Relatório
30 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$5.71M
/
-$0.45
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-15.82%
/
-8.16%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+54.40%
/
+60.71%

Vivos Therapeutics, Inc. Common Stock earnings per share and revenue

On 19 de nov. de 2025, VVOS reported earnings of -0.49 USD per share (EPS) for Q3 25, beating the estimate of -0.52 USD, resulting in a 5.81% surprise. Revenue reached 6.78 milhão, compared to an expected 4.91 milhão, with a 38.20% difference. The market reacted with a -10.17% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analistas forecast an EPS of -0.45 USD, with revenue projected to reach 5.71 milhão USD, implying an diminuir of -8.16% EPS, and diminuir of -15.82% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
26 de dez. de 2025 Para Q4 25
Estimativa
-$0.49
Real
-
Surpresa
-
FAQ
For Q3 2025, Vivos Therapeutics, Inc. Common Stock reported EPS of -$0.49, beating estimates by 5.81%, and revenue of $6.78M, 38.2% above expectations.
The stock price moved down -10.17%, changed from $2.36 before the earnings release to $2.12 the day after.
The next earning report is scheduled for 30 de mar. de 2026.
Based on 5 analistas, Vivos Therapeutics, Inc. Common Stock is expected to report EPS of -$0.45 and revenue of $5.71M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio